Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders allowing patients to overcome disease and live a better life.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $50M
Founded date: 2015
Investors 6
| Date | Name | Website |
| - | Aberdare V... | aberdare.c... |
| - | KittyHawk ... | kittyhawk.... |
| - | Omega Fund... | omegafunds... |
| - | Chiesi Ven... | chiesivent... |
| - | Solasta Ve... | solasta-ve... |
| - | Bay City C... | baycitycap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.07.2017 | Series B | $50M | - |
Mentions in press and media 5
| Date | Title | Description |
| 22.07.2024 | Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis | SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 27.02.2024 | Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis | SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China's National Medica... |
| 25.07.2017 | Kezar Life Sciences Secures $50M in Series B Financing | Kezar Life Sciences, a South San Francisco, Calif.-based clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting the immunoproteasome and the protein secretion pathway, closed a $50m Series B funding.... |
| 25.07.2017 | Cormorant Leads $50M Series B for Kezar Life Sciences | Kezar Life Sciences, a private, clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting the immunoproteasome and the protein secretion pathway, announced today that it has closed an oversubscribed Ser... |
| 16.06.2015 | Kezar Life Sciences Completes $23M Series A Financing | Kezar Life Sciences, a South San Francisco, CA-based company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders, completed a $23m Series A financing. Backers included Morningside Venture... |